- Tags: gene therapyretina
Pipeline
RegenxBio doses first patient in phase 2b/3 trial for DR
One-time gene therapy continues to move down the pipeline, with presentations on efficacy and safety data expected at ASRS.
Research
Leukemia may appear in RVO prior to diagnosis
Ocular findings linked to leukemia may emerge before systemic symptoms, with retinal vascular changes sometimes serving as an early clinical clue.
Research
Study identifies stroke risks following ischemic ocular events
Nearly one in four patients had a stroke or transient ischemic attack within a year.
Pipeline
Atsena doses first patient in phase 3 XLRS LIGHTHOUSE trial
Enrollment is expected to finish in Q1 2027, with topline results anticipated in H1 2028.
Products
Lumibird Medical launches wireless IntegreLIO system
First truly wireless integrated LIO enables unrestricted freedom of movement for physicians performing PRP and other peripheral retinal treatments.
Research
White blood cell counts higher among CRAO patients
Higher systemic leukocyte and lymphocyte levels point to subtype-specific inflammatory profiles.
Pipeline
Alkeus begins dosing in global phase 3 Stargardt trial on oral gildeuretinol
Phase 3 NORTHSTAR study seeks to build on growing evidence that ALK-001 benefits low luminance visual acuity.
Products
FDA approves Lupin's Lucentis biosimilar injection
Ranluspec (ranibizumab-hkdz) marks the third ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Pipeline
Oculis's phase 3 DME eye drop trial fails primary goals
While OCS-01 was well-tolerated, the DIAMOND program did not meet either outcome measures; company will not seek an FDA NDA filing.
Business
Lexitas acquires Erie Retina Research to expand ophthalmic trials
Partnership also involves integration of CASExERIE and Element Erie: Imaging and Reading Center to establish a fully integrated retina research platform.
Business
NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition
Retinal imaging developer adds Durin Life Sciences’ noninvasive, blood-based biomarker test to its integrated platform targeting cognitive diseases.
Research
Vitreous floaters may predict RD development
Cohort study finds new-onset floaters, particularly when acute or numerous, confer a higher absolute risk of retinal detachment than flashes alone.
Products
Remidio's portable fundus camera offers point-of-care imaging
FDA-cleared and smartphone-based diagnostic device offers complete imaging for both eyes in less than 1 minute—across a wide range of clinical settings.
Research
Oculis's global DME consensus study identifies critical gaps in care
Expert panel highlights disease management while emphasizing the importance of early intervention and non-invasive treatment options based on BCVA outcomes.
Pipeline
Atsena releases positive XLRS interim data from LIGHTHOUSE study
Enrollment for Part C of the study is underway, with the company targeting a 2028 BLA submission for ATSN-201, an investigational gene therapy.
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Events
Retina Summit 2026: DR referrals and genetic testing for ODs
AAO’s one-day meeting explored retina care’s shift from referral-based to decision-making at the OD level.
Pipeline
MeiraGTx acquires J&J's XLRP investigational therapy
Deal includes all interests in botaretigene sparoparvovec (bota-vec); company plans to immediately file for global regulatory approval.
Pipeline
Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt
Full submission planned for Q2 2026, once-daily tablet has potential to become the first-ever treatment approved for this patient base.
Research